Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
复制标题
DOI：
10.1038/bjc.2013.520
复制
发表时间：
2013-09-17
影响因子：
8.8
通讯作者：
Iyama, K-I
中科院分区：
文献类型：
--
作者：
Iwase, H.;Yamamoto, Y.;Yamamoto-Ibusuki, M.;Murakami, K-I;Okumura, Y.;Tomita, S.;Inao, T.;Honda, Y.;Omoto, Y.;Iyama, K-I
雌激素通常刺激雌激素受体（ER）阳性乳腺癌的进展。特别地，高剂量雌激素在某些情况下抑制这些肿瘤的生长。我们前瞻性研究了炔雌醇治疗（每天3 mg口服）绝经后晚期或复发性ER阳性乳腺癌患者的疗效和安全性，这些患者既往接受过内分泌治疗，尤其是对芳香酶抑制剂耐药的患者。18例患者入组，中位年龄为63岁，平均观察时间为9.2个月。3例病例在1周内因雌激素爆发反应伴恶心、疲劳和肌肉骨骼疼痛退出研究。有效率为50%（9/18），临床受益率为56%（10/18）。病情稳定（<6个月）3例（17%），进展2例（2%）。至治疗失败的时间（包括2例接受治疗的患者）的中位数为5.6个月（范围为0.1至14.5+）。虽然在接受长期治疗的患者中观察到阴道出血或子宫内膜增厚，但没有严重的不良事件，如深静脉血栓形成或其他恶性肿瘤。虽然这种治疗的机制尚未完全理解，但我们的数据可能有助于改变晚期内分泌治疗的共同观点。
Oestrogens usually stimulate the progression of oestrogen receptor (ER)-positive breast cancer. Paradoxically, high-dose oestrogens suppress the growth of these tumours in certain circumstances. We prospectively examined the efficacy and safety of ethinylestradiol treatment (3 mg per day oral) in postmenopausal patients with advanced or recurrent ER-positive breast cancer who had previously received endocrine therapies, especially those with resistance to aromatase inhibitors. Eighteen patients were enrolled with the median age of 63 years and the mean observation time of 9.2 months. Three cases withdrew within 1 week due to oestrogen flare reactions with nausea, fatigue and muscle-skeletal pain. The response rate was 50% (9 out of 18), and the clinical benefit rate was 56% (10 out of 18). The stable disease (<6 months) was 17% (3 out of 18) and another 2 cases were judged as progressive disease. Time-to-treatment failure including 2 on treatment was a median of 5.6 months (range 0.1 to 14.5+). Although vaginal bleeding or endometrial thickening was observed in patients receiving long-term treatment, there were no severe adverse events, such as deep venous thrombosis or other malignancies. Although the mechanism of this treatment has not been fully understood, our data may contribute to change the common view of late-stage endocrine therapy.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
3.2
作者：
Mahtani, Reshma L.;Stein, Alisha;Vogel, Charles L.
通讯作者：
Vogel, Charles L.
影响因子：
3.9
作者：
Santen, RJ;Song, RX;Yue, W
通讯作者：
Yue, W
DOI：
10.1093/jnci/93.22.1714
发表时间：
2001-11-21
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Song, RXD;Mor, G;Santen, RJ
通讯作者：
Santen, RJ
影响因子：
7.5
作者：
Yamamoto-Ibusuki, Mutsuko;Yamamoto, Yutaka;Iwase, Hirotaka
通讯作者：
Iwase, Hirotaka